Immunovia AB (publ) financials
Immunovia AB (publ)
549300KHWL6KK1XGUO81 | Line item | 2023 | 2022 |
|---|---|---|
| Income statement | ||
| Revenue | SEK 1.8M | SEK 1.2M |
| Employee benefits expense | -SEK 79.6M | -SEK 85.2M |
| Raw materials & consumables used | -SEK 6.7M | -SEK 4.2M |
| Depreciation & amortisation | -SEK 141.7M | -SEK 24.9M |
| Operating profit (EBIT) | -SEK 296.5M | -SEK 191.2M |
| Net finance income / (cost) | -SEK 13.0M | SEK 23.1M |
| Finance costs | -SEK 19.3M | -SEK 18.2M |
| Profit before tax | -SEK 309.4M | -SEK 168.1M |
| Income tax expense | SEK 0 | SEK 0 |
| Profit for the year | -SEK 309.4M | -SEK 168.1M |
| Total comprehensive income | -SEK 298.1M | -SEK 190.7M |
| Per share | ||
| Diluted EPS | SEK -7.95 | SEK -7.43 |
| Free cash flow / share | SEK -3.78 | SEK -7.82 |
| Cash flow statement | ||
| Cash generated from operations | -SEK 154.2M | -SEK 168.4M |
| Net cash from operating activities | -SEK 147.1M | -SEK 175.6M |
| Net cash from investing activities | SEK 3.2M | -SEK 1.6M |
| Purchase of PP&E (capex) | SEK 0 | SEK 1.3M |
| Purchase of intangibles | SEK 1.1M | SEK 368.0K |
| Net cash from financing activities | SEK 114.7M | -SEK 5.1M |
| Lease liability payments | SEK 6.5M | SEK 5.7M |
| Net change in cash | -SEK 29.1M | -SEK 182.3M |
| Balance sheet | ||
| Total assets | SEK 98.7M | SEK 300.6M |
| Non-current assets | SEK 18.2M | SEK 185.0M |
| Property, plant & equipment | SEK 15.1M | SEK 47.9M |
| Right-of-use assets | SEK 10.2M | SEK 36.7M |
| Intangible assets & goodwill | SEK 2.5M | SEK 133.6M |
| Current assets | SEK 80.5M | SEK 115.6M |
| Inventories | SEK 0 | SEK 2.0M |
| Trade & other receivables | SEK 146.0K | SEK 253.0K |
| Cash & equivalents | SEK 76.8M | SEK 106.0M |
| Total equity | SEK 67.0M | SEK 243.8M |
| Non-current liabilities | SEK 1.8M | SEK 32.7M |
| Lease liabilities (non-current) | SEK 1.8M | SEK 32.7M |
| Current liabilities | SEK 29.9M | SEK 24.1M |
| Lease liabilities (current) | SEK 2.5M | SEK 4.9M |
| Derived metrics | ||
| Free cash flow | -SEK 147.1M | -SEK 176.8M |
| Operating margin | -16451.7% | -15876.2% |
| Net margin | -17172.0% | -13961.1% |
| Return on equity | -461.9% | -68.9% |
| Cash conversion ratio | 0.48× | 1.04× |
| Capex coverage | — | -139.79× |
| Other reported items | ||
| Accruals and Deferred Income Including Contract Liabilities | SEK 15.0M | SEK 15.2M |
| Additional Paidin Capital | — | SEK 639.0K |
| Adjustments For Decrease Increase In Other Current Assets | SEK 2.0M | SEK 438.0K |
| Adjustments For Decrease Increase In Trade and Other Receivables | SEK 4.7M | SEK 298.0K |
| Adjustments For Increase Decrease In Trade and Other Payables | SEK 409.0K | -SEK 7.9M |
| Adjustments For Reconcile Profit Loss | SEK 140.5M | SEK 23.5M |
| Cash Flows From Used In Decrease Increase In Shortterm Deposits and Investments | SEK 2.9M | SEK 0 |
| Current Prepaid Expenses | SEK 2.8M | SEK 4.3M |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | -SEK 136.0K | SEK 948.0K |
| Equity and Liabilities | SEK 98.7M | SEK 300.6M |
| Expense By Nature | -SEK 298.3M | -SEK 192.4M |
| Finance Income | SEK 6.3M | SEK 41.3M |
| Income Taxes Paid Refund Classified As Financing Activities | SEK 0 | SEK 0 |
| Intangible Assets Other Than Goodwill | SEK 0 | SEK 110.1M |
| Interest Paid Classified As Financing Activities | -SEK 1.2M | -SEK 1.5M |
| Interest Received Classified As Operating Activities | SEK 2.9M | SEK 745.0K |
| Issue of Equity | — | SEK 151.8M |
| Issued Capital | SEK 2.3M | SEK 1.1M |
| Number of Shares Issued | 45.3M | 22.6M |
| Other Comprehensive Income | SEK 11.4M | -SEK 22.6M |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | SEK 11.4M | -SEK 22.6M |
| Other Current Nonfinancial Assets | SEK 797.0K | SEK 3.0M |
| Other Expense By Nature | -SEK 68.7M | -SEK 77.7M |
| Other Liabilities | SEK 3.9M | SEK 2.5M |
| Other Noncurrent Financial Assets | SEK 506.0K | SEK 3.5M |
| Other Operating Income Expense | SEK 227.0K | SEK 59.0K |
| Other Reserves | -SEK 12.9M | -SEK 24.3M |
| Proceeds From Issuing Other Equity Instruments | — | SEK 639.0K |
| Proceeds From Issuing Shares | SEK 121.2M | SEK 0 |
| Proceeds From Sales of Property Plant and Equipment Classified As Investing Activities | SEK 1.3M | SEK 0 |
| Retained Earnings | -SEK 1.06B | -SEK 749.4M |
| Revenue From Royalties | SEK 1.6M | SEK 1.1M |
| Share Issue Related Cost | -SEK 30.6M | — |
| Share Premium | SEK 1.14B | SEK 1.02B |
| Trade and Other Payables To Trade Suppliers | SEK 8.5M | SEK 1.6M |
| Weighted Average Shares | 38.9M | 22.6M |
Every line item above is a fact tagged in Immunovia AB (publ)'s annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (SEK), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.